Clay Siegall graduated from the University of Maryland with a bachelor of science in zoology. He later furthered his studies at George Washington University and graduated with a Ph.D. in Genetics. Mr Siegall career began in 1988. He got a job with National Institute of Health and worked with them until 1991.In 1991, he joined Bristol-Myers Squibb pharmaceutical. He worked for this research institute for seven years.
To achieve his full potential, he founded Seattle Genetics in the year 1998.Today, Clay Siegall serves as the President, Chief Executive Officer, and the chairman of the board of Seattle Genetics. Siegall has a vast experience in the pharmaceutical industry. He is a director of the board at three pharmaceutical industries. In Alders pharmaceuticals, he has been on the committee since 2006. While in Mirna Therapeutics he has worked for three years. Lastly, he sits on the board of directors at Ultragenyx Pharmaceutical since 2014.
Siegall is a scientist and has aimed his research on drugs and methods of suppressing cancer. The drive to help and support patients only pushed him further in starting the company. He founded and built Seattle Genetics on the pillars of innovation, research, and passion for aiding patients. By developing antibody-drug conjugates (ADCs) used in the treatment of cancer, Siegall has led the company to its current leadership position. The company lists among the best research firm that has actively participated in cancer cure research.
His leadership role has enabled the company to enter into multiple strategic licenses for its (ADC) technology. Overall, these strategic licenses have generated a revenue of over 300 million dollars. The technology developed by Seattle Genetics has made it possible for the development of over 20 ADCs. While Seattle Genetics cannot produce all these ADCs, they have made it possible by having internal and collaborator programs. Seagall has also actively participated in capital raising activities for the company. He has been able to acquire over 600 million dollars by both public and private financing. He also saw the company through their first initial public offering in the year 2001.